Αρχική World News Oncogenic Drivers Associated with Late Recurrence in Postmenopausal Women with ER-positive/HER2-negative Early...

Oncogenic Drivers Associated with Late Recurrence in Postmenopausal Women with ER-positive/HER2-negative Early Breast Cancer

Prof. Sherene Loi of the Peter MacCallum Cancer Centre, University of Melbourne in Melbourne, Victoria, Australia and the BIG 1-98 study investigators reported on 8 July 2020 in the Annals of Oncology that in women with oestrogen receptor (ER)-positive/HER2-negative postmenopausal early breast cancer, PIK3CA mutations are associated with reduced risk of late distant recurrence, whereas amplifications on 8p11 and BRCA2 mutations are associated with increased risk of late distant recurrence. The characterisation of oncogenic driver alterations may aid in refining treatment choices for late disease recurrence in that setting and help in identifying potential drug targets for testing in future clinical trials.

The BIG 1-98 team wrote in the study background that in patients with postmenopausal, ER-positive/HER2-negative early breast cancer, the risk for distant recurrence extends beyond 5 years of adjuvant hormonal treatment.

In their study, the investigators aimed to identify genomic driver alterations associated with late distant recurrence. They used next generation sequencing to characterise driver alterations in primary tumours from a subset of 764 postmenopausal patients with ER-positive/HER2-negative breast cancer included in the BIG 1-98 randomised trial.

Late distant recurrence events were defined as at least 5 years from time of randomisation. The association of driver alterations with distant recurrence-free interval in early and late time periods was assessed using Cox regression models. Multivariable analyses were performed to adjust for clinicopathological factors. Weighted analysis methods were used in order to correct for over-sampling of distant recurrences.

In total, 538 of 764 samples (70%) were successfully sequenced including 88 early (63%) and 52 late (37%) distant recurrence events after a median follow-up of 8.1 years.

In univariable analysis for late distant recurrence, PIK3CA mutations (58.8%) were significantly associated with reduced risk (hazard ratio [HR] 0.40, 95% confidence interval [CI] 0.20-0.82, p = 0.012), whereas amplifications on chromosome 8p11 (10.9%) (HR 4.79, 95% CI 2.30-9.97, p < 0.001) and BRCA2 mutations (2.3%) (HR 5.39, 95% CI 1.51-19.29, p = 0.010) were significantly associated with an increased risk.

In multivariable analysis, only amplifications on 8p11 (p = 0.002) and BRCA2 mutations (p = 0.013) remained significant predictors.

The authors concluded that oncogenic driver characterisation may aid in refining prognostic estimates for late disease recurrence in women with ER-positive/HER2-negative postmenopausal early breast cancer.

Reference

Luen SJ, Asher R, Lee CK, et al. Identifying oncogenic drivers associated with increased risk of late distant recurrence in post-menopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study. Annals of Oncology; Published 8 July 2020. DOI: https://doi.org/10.1016/j.annonc.2020.06.024

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...

Prostate Cancer

The article is provided by Scientific Communications Officer of NIPD Genetics, Ms Marina Charitou (MSc) Prostate Cancer Awareness Prostate cancer is the second most common cancer...
- Advertisment -

Ροή Ειδήσεων

EMA Recommends Granting a Conditional Marketing Authorisation for Autologous Anti-CD19-Transduced CD3+ Cells

On 15 October 2020, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting...

New Treatment Helps Survivors Regain Sensation After Breast Cancer

When NBC’s Kristen Dahlgren was diagnosed with breast cancer, she didn’t think much about the lack of sensation that her mastectomy would likely leave...

Is there a future without Pap testing?

Maybe you saw the hashtag #DonutTakePAPAway on social media recently? ObGyn physicians and advocates are voicing their disagreement with the American Cancer Society’s (ACS)...

Mother Spent 14 Weeks Battling Breast Cancer Alone During COVID-19 Lockdown

Battling cancer is difficult for anyone, but it’s even harder when you have to do it alone. That’s what happened to Samantha Currie. Samantha, 27,...

ESMO 2020: New Treatments for Advanced Kidney Cancer, Prostate Cancer, and Bladder Cancer

The 2020 European Society for Medical Oncology (ESMO) Virtual Congress was held online from September 19 to September 21. In this podcast, Neeraj Agarwal,...

The UK Government’s spending review: Time to invest in the future of cancer care

This autumn, the chancellor Rishi Sunak will go to Parliament and set out the UK Government’s spending priorities in the Comprehensive Spending Review...